Synthetic biology is one of the fastest growing fields in terms of both information and capital generation. In 2012, The World Economic Forum ranked it as the second most important emerging technology of the 21st century; and while it does not explicitly appear on the 2016 list, half of the emerging technologies are enabled by […]
In early 2017, the Oncology Center of Excellence (OCE) was established by the U.S. Food and Drug Administration (FDA) to modernize the cancer drug approval process by increasing intra-agency collaboration and promoting novel regulatory ideas and processes. Among critical, medical innovation initiatives, the 21st Century Cures Act (Cures) directed the agency to create inter-center institutes in major disease areas […]
This December the United States will enter the 46th year of its longest ongoing war: the war on cancer. During this time, we have lost more lives to this disease than all U.S. military casualties since the birth of our country.
On May 23rd 2017, the cancer research community applauded a landmark accomplishment when for the first time the U.S. Food and Drug Administration (FDA) approved Merck’s pembrolizumabfor use in tumors located in any tissue. While cancers are traditionally organized and treated based on their tissue of origin, tumor sequencing has demonstrated that there are important genetic […]
When the March for Science was first announced, I wasn’t planning to go. I was unsure what role scientists should have in politics and wary of increasing the already harmful levels of partisanship towards science. However, the discussion surrounding the march convinced me: Science is crucial for our government and for the creation of policies […]